NCT07827963 · NOT YET RECRUITING

VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism

This study watches how people with Parkinson's disease and related conditions remember spaces, both on a tabletop and while walking. Researchers use block-tapping tests, motion sensors and eye-tracking glasses. It is an observational pilot, meaning small and early, with no treatment given. It aims to see whether navigation memory slips first.

Eligibility criteria

Inclusion Criteria
* Male and female subjects aged between 35 and 80 years;
* Diagnosis of Parkinson's disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria;
* Diagnosis of primary atypical parkinsonism MSA-P, according to the Second Consensus Statement on the Diagnosis of Multiple System Atrophy;
* Diagnosis of primary atypical parkinsonism PSP-P, according to the Movement Disorder Society criteria for Progressive Supranuclear Palsy;
* Modified Hoehn and Yahr stage between 1 and 3 during the "ON" phase (Hoehn and Yahr, 1967);
* Cognitive screening with the Montreal Cognitive Assessment (MoCA) score > 17;
* Mini-Mental State Examination (MMSE) score ≥ 24 (Folstein et al., 1975);
* Ability to walk independently for 10 meters without assistive devices;
* Ability to understand and sign the informed consent form;
* Ability to comply with study procedures.
Exclusion Criteria
* Diagnosis of neurological disorders other than Multiple System Atrophy (MSA) and Parkinson's disease;
* Depressive disorders or Beck Depression Inventory-II (BDI-II) score > 20;
* Musculoskeletal disorders that could impair gait performance.
The study will enroll 20 healthy subjects, matched by age and sex with patients affected by Parkinson's disease (PD) and atypical parkinsonism who will be recruited into the study.
The same inclusion criteria will be applied to both groups of patients with Multiple System Atrophy (MSA) and Parkinson's disease.
The exclusion criteria will be:
* Diagnosis of neurological disorders;
* Depressive disorders or Beck Depression Inventory-II (BDI-II) score > 20;
* Musculoskeletal disorders that could impair gait performance.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-09-18

View full record on ClinicalTrials.gov

All APOE4 clinical trials